# Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

> **NCT07512362** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Bernard (Barry) Baumel** · enrollment: 10 (estimated)

## Conditions studied

- Mild Cognitive Impairment
- Early Alzheimer's Disease
- AD-MCI

## Interventions

- **BIOLOGICAL:** human Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT07512362
- **Lead sponsor:** Bernard (Barry) Baumel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-06-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07512362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07512362, "Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07512362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*